ANN ARBOR, Michigan (FOX 2) – AstraZeneca announced this week that its vaccine candidate has entered the final phase of the United States.
The Cambridge, England-based company said the exam would now involve up to 30,000 adults of racial, ethnic and geographic teams, and the University of Michigan is one of many sites supporting the trial.
U-M will begin recruiting tons of participants for the trial without delay until the trial is complete.The Phase III portion of this trial will be conducted in U.S. over a two-year period.
Phase I/II trials of the vaccine in more than 1,000 other people were completed earlier this year and showed an increase in antibody responses opposite SARS-CoV-2 and no serious adverse effects.
To be eligible to participate in the next phase of the trial, you must be at least 18 years of age, healthy or solid, and have not demonstrated a diagnosis of COVID-19 in the past.
You can get more data and, in all likelihood, signal here.
Advertisement
AstraZeneca said the progression of the vaccine, known as AZD1222, is advancing internationally with complex trials also in the UK, Brazil and South Africa.More trials are planned in Japan and Russia.
The AstraZeneca trial is one of many vaccine trials funded through a public/private partnership under the U.S. Department of Health and Human Services.But it’s not the first time Called Operation Warp Speed and is designed to drive the progression of a life-saving vaccine to save COVID-19, maintaining standards of protection and effectiveness.
“We are proud to promote the University of Michigan’s remarkable legacy of excellence in vaccine testing through this vital association of clinical trials.We look forward to an effective vaccine that opposes COVID-19 and save lives soon,” said Mark Schlissel, MD, Ph.D., president of the University of Michigan.
Two other candidate vaccines began the last tests this summer on tens of thousands of people in the United States: one created through the National Institutes of Health and manufactured through Moderna Inc., and the other evolved through Pfizer Inc.BioNTech in Germany.
“Bringing a single vaccine to the last phase of trials 8 months after the discovery of a virus would be a remarkable achievement; have 3 at the time with others in it is extraordinary,” the secretary of Health and Human Services, Alex Azar, said in a statement.
You can see a panel of vaccines that have already been tested or are about to be tested at the final level here.